

B-Cell Maturation Antigen (BCMA): A Promising Target for Relapsed/Refractory Multiple Myeloma

PowerPak Recorded Podcast

References:

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma. Version 4.2020. Published May 8, 2020. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
2. Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic options. *Leukemia*. 2020;34(4):985–1005.
3. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N Engl J Med*. 2019;380(18):1726–37.
4. Topp M, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. *J Clin Oncol*. 2020;38(8):775–83.
5. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomized, open-label, phase 2 study. *Lancet Oncol*. 2020;21(2):207–21.
6. Lonial S, Lee HC, Badros A, et al. Pivotal DREAMM-2 study: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). *J Clin Oncol*. 2020;38(15_suppl):8536.
7. Munshi N, Andersen LD, Shah N, et al; on behalf of the KarMMa Study Investigators. Idecabtagene vicleucel (ide-cel;bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. *J Clin Oncol*. 2020;38(15_suppl):8503.
8. Berdeja JG, Madduri D, Usmani SZ, et al. Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, in relapsed/refractory multiple myeloma. *J Clin Oncol*. 2020;38(15_suppl):8505.